Author:
Zhang B,Groffen J,Heisterkamp N
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference35 articles.
1. Ren R . Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukemia. Nat Rev Cancer 2005; 5: 172–183.
2. Heisterkamp N, Groffen J . BCR/ABL Gene Structure and BCR Function. In: Carella AM, Daley GQ, Eaves CJ, Goldman JM and Hehlman, R (Eds.). Chronic Myeloid Leukemia: Biology and Treatment 2001, pp 3–17.
3. Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, Choe K et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 2001; 97: 1404–1412.
4. Reichert A, Heisterkamp N, Daley GQ, Groffen J . Treatment of Bcr/Abl-positive ALL in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood 2001; 97: 1399–1403.
5. Hoover RR, Mahon FX, Melo JV, Daley GQ . Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002; 100: 1068–1071.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献